15 June 2017 - Adamis Pharmaceuticals said on Thursday it received U.S. approval for its emergency epinephrine syringes to treat severe allergic reactions that it intends to be a lower cost rival to Mylan's widely used EpiPen, sending its shares up more than 50%.

The company said it was looking for a marketing partner and would set a price for the product before its launch sometime in the second half of this year.

Adamis said its pre-filled epinephrine syringes would be sold under the brand name Symjepi.

Read Reuters article